PMID- 23298486
OWN - NLM
STAT- MEDLINE
DCOM- 20130423
LR  - 20171116
IS  - 0394-6320 (Print)
IS  - 0394-6320 (Linking)
VI  - 25
IP  - 4
DP  - 2012 Oct-Dec
TI  - Ethyl pyruvate administration suppresses growth and invasion of gallbladder 
      cancer cells via downregulation of HMGB1-RAGE axis.
PG  - 955-65
AB  - High mobility group box B1 (HMGB1)-receptor for advanced glycation end products 
      (RAGE) axis has been previously known to be involved in carcinogenesis and 
      development of multiple malignancies. Some studies have confirmed that Ethyl 
      pyruvate (EP), a potent inhibitor of HMGB1, exerts the therapeutic effects on 
      metastatic live tumor from gastric cancer. However, the effects and possible 
      molecular mechanisms of EP on gallbladder cancer (GBC) need to be further 
      explored. In the present study, human GBC cell lines (GBC-SD and SGC-996) were 
      treated with different concentrations of EP. Then, the expression levels of 
      HMGB1, RAGE and some transcription factors were identified by Real-time PCR and 
      Western blot assays. Cell proliferative activities indicated by MTT assay, 
      invasive potential by Transwell assay and cell apoptosis and cycle distribution 
      were performed for functional analysis of GBC cell lines in vitro. As a result, 
      EP decreased the expression of HMGB11, RAGE, PCNA and matrix metallopeptidase-9 
      (MMP-9), while it increased the expression of p53. Moreover, EP administration 
      decreased GBC cell proliferation, inhibited the invasive potential, and induced 
      apoptosis and cycle arrest in S phase in GBC cells. In conclusion, EP 
      administration inhibits growth and invasion of gallbladder cancer cells possibly 
      via down-regulation of the HMGB1-RAGE axis, suggesting that EP may play a 
      critical role in the treatment of cancer in conjunction with other therapeutic 
      agents.
FAU - Li, M-L
AU  - Li ML
AD  - Department of General Surgery, Shanghai Jiaotong University, Shanghai, China.
FAU - Wang, X-F
AU  - Wang XF
FAU - Tan, Z-J
AU  - Tan ZJ
FAU - Dong, P
AU  - Dong P
FAU - Gu, J
AU  - Gu J
FAU - Lu, J-H
AU  - Lu JH
FAU - Wu, X-S
AU  - Wu XS
FAU - Zhang, L
AU  - Zhang L
FAU - Ding, Q-C
AU  - Ding QC
FAU - Wu, W-G
AU  - Wu WG
FAU - Rao, L-H
AU  - Rao LH
FAU - Mu, J-S
AU  - Mu JS
FAU - Yang, J-H
AU  - Yang JH
FAU - Weng, H
AU  - Weng H
FAU - Ding, Q
AU  - Ding Q
FAU - Zhang, W-J
AU  - Zhang WJ
FAU - Chen, L
AU  - Chen L
FAU - Liu, Y-B
AU  - Liu YB
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Int J Immunopathol Pharmacol
JT  - International journal of immunopathology and pharmacology
JID - 8911335
RN  - 0 (HMGB1 Protein)
RN  - 0 (Pyruvates)
RN  - 0 (Receptor for Advanced Glycation End Products)
RN  - 0 (Receptors, Immunologic)
RN  - 03O98E01OB (ethyl pyruvate)
SB  - IM
MH  - Apoptosis/drug effects
MH  - Cell Cycle/drug effects
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Down-Regulation
MH  - Gallbladder Neoplasms/*drug therapy/pathology
MH  - HMGB1 Protein/*antagonists & inhibitors/genetics
MH  - Humans
MH  - Neoplasm Invasiveness
MH  - Pyruvates/*pharmacology
MH  - Receptor for Advanced Glycation End Products
MH  - Receptors, Immunologic/*antagonists & inhibitors/genetics
EDAT- 2013/01/10 06:00
MHDA- 2013/04/24 06:00
CRDT- 2013/01/10 06:00
PHST- 2013/01/10 06:00 [entrez]
PHST- 2013/01/10 06:00 [pubmed]
PHST- 2013/04/24 06:00 [medline]
AID - 13 [pii]
AID - 10.1177/039463201202500413 [doi]
PST - ppublish
SO  - Int J Immunopathol Pharmacol. 2012 Oct-Dec;25(4):955-65. doi: 
      10.1177/039463201202500413.